How has been the historical performance of Ishita Drugs?

Answer:The historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years. Breakdown: Ishita Drugs' net sales have fluctuated over the years, reaching 15.00 Cr in Mar'25, slightly down from 15.19 Cr in Mar'24, but up from 12.07 Cr in Mar'23. The total operating income mirrored this trend, with a peak of 15.00 Cr in Mar'25. Raw material costs decreased to 10.11 Cr in Mar'25 from 11.37 Cr in Mar'24, while employee costs remained stable at 1.34 Cr. The total expenditure, excluding depreciation, was 14.00 Cr in Mar'25, a decrease from 14.28 Cr in Mar'24. Operating profit, excluding other income, improved to 1.00 Cr in Mar'25 from 0.91 Cr in Mar'24, contributing to an operating profit margin of 6.67%. Profit before tax increased to 1.16 Cr in Mar'25, up from 0.99 Cr in Mar'24, leading to a profit after tax of 0.87 Cr in Mar'25, compared to 0.75 Cr in Mar'24. The earnings per share rose to 2.91 in Mar'25 from 2.51 in Mar'24, indicating a positive trend in profitability. Cash flow from operating activities was 2.00 Cr in Mar'24, with a net cash inflow of 1.00 Cr, reflecting a stable cash position with closing cash and cash equivalents at 4.00 Cr in Mar'24. Overall, Ishita Drugs has shown resilience in its financial performance, with gradual improvements in profitability and cash flow management.